P2Y₁₂ and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP

References

• Savi P, Herbert JM. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost 2005; 31: 174–83
   PubMed Web of Science ®Google Scholar
• Jakubowski JA, Winters KJ, Naganuma H, Wallentin L. Prasugrel: A novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovasc Drug Rev 2007; 25: 357–374
   Google Scholar
• Savi P, Pereillo JM, Uzabiaga MF, Combalbert J, Picard C, Maffrand JP, Pascal M, Herbert JM. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000; 84: 891–896
   PubMed Web of Science ®Google Scholar
• Pereillo JM, Maftouh M, Andrieu A, Uzabiaga MF, Fedeli O, Savi P, Pascal M, Herbert JM, Maffrand JP, Picard C. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos 2002; 30: 1288–1295
   PubMed Web of Science ®Google Scholar
• Judge HM, Buckland RJ, Sugidachi A, Jakubowski JA, Storey RF. The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses. Platelets 2008; 19: 125–133
   PubMed Web of Science ®Google Scholar
• Van Giezen JJ, Humphries RG. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Semin Thromb Hemost 2005; 21: 195–204
   Google Scholar
• Storey RF, Oldroyd KG, Wilcox RG. Open multicentre study of the P2T receptor antagonist ARC69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Thromb Haemost 2001; 85: 401–407
   PubMed Web of Science ®Google Scholar
• Husted S, van Giezen JJ. Ticagrelor: The first reversibly binding oral P2Y12 receptor antagonist. Cardiovasc Ther 2009; 27: 259–274
   PubMed Web of Science ®Google Scholar
• Van Giezen JJ, Nilsson L, Berntsson P, Wissing BM, Giordanetto F, Tomlinson W, Greasley PJ. Ticagrelor binds to P2Y12 receptors independently from ADP but antagonizes ADP-induced receptor signalling and platelet aggregation. J Thromb Haemost 2009; 7: 1556–1565
   PubMed Web of Science ®Google Scholar
• Cattaneo M. New P2Y12 inhibitors. Circulation 2010; 121: 171–179
   PubMed Web of Science ®Google Scholar
• Storey RF, Sanderson HM, May JA, White AE, Cameron KE, Heptinstall S. The central role of the P2T receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. Br J Haematol 2000; 110: 925–934
   PubMed Web of Science ®Google Scholar
• Dorsam RT, Kunapuli S. Central role of the P2Y12 receptor in platelet activation. J Clin Invest 2004; 113: 340–344
   PubMed Web of Science ®Google Scholar
• Gachet C. P2 receptors, platelet function and pharmacological implications. Thromb Haemost 2008; 99: 466–472
   PubMed Web of Science ®Google Scholar
• Heptinstall S, Espinosa DI, Manolopoulos P, Glenn JR, White AE, Johnson A, Dovlatova N, Fox SC, May JA, Hermann D, et al. DG-041 inhibits the EP3 prostanoid receptor – A new target for inhibition of platelet function in atherothrombotic disease. Platelets 2008; 19: 605–613
   PubMed Web of Science ®Google Scholar
• Singh J, Zeller W, Zhou N, Hategen G, Mishra R, Polozov A, Yu P, Onua E, Zhang J, Zembower D, et al. Identification of DG-041, a potent and selective prostanoid EP3 receptor antagonist, as a novel anti-platelet agent. ACS Chem Biol 2009; 4: 115–126
   PubMed Web of Science ®Google Scholar
• Fabre JE, Gurney ME. Limitations of current therapies to prevent thrombosis: A need for novel strategies. Mol Bio Syst 2010; 6: 305–315
   Google Scholar
• Singh J, Zeller W, Zhou N, Hategan G, Mishra RK, Polozov A, Yu P, Onua E, Zhang J, Ramírez JL, et al. Structure-activity relationship studies leading to the identification of (2E)-3-[l-[(2,4-dichlorophenyl)methyl]-5-fluoro-3-methyl-lH-indol-7-yl]-N-[(4,5-dichloro-2-thienyl)sulfonyl]-2-propenamide (DG-041), a potent and selective prostanoid EP3 receptor antagonist, as a novel antiplatelet agent that does not prolong bleeding. J Med Chem 2010; 53: 18–36
   Google Scholar
• Armstrong RA. Platelet prostanoid receptors. Pharmacol Ther 1996; 72: 171–191
   PubMed Web of Science ®Google Scholar
• Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: Structures, properties and functions. Physiol Rev 1999; 79: 193–226
   Google Scholar
• Norel X. Prostanoid receptors in the human vascular wall. ScientificWorldJournal 2007; 7: 1359–1374
   PubMed Web of Science ®Google Scholar
• Cooper JA, Hill SJ, Alexander SPH, Rubin PC, Horn EH. Adenosine receptor-induced cyclic AMP generation and inhibition of 5-hydroxytryptamine release in human platelets. Br J Clin Pharmacol 1995; 40: 43–50
   Google Scholar
• Amisten S, Braun OÖ, Bengtsson A, Erlinge D. Gene expression profiling for the identification of G-protein coupled receptors in human platelets. Thromb Res 2008; 122: 47–57
   PubMed Web of Science ®Google Scholar
• Yang D, Chen H, Koupenova M, Carroll SH, Eliades A, Freedman JE, Toselli P, Ravid K. A new role for the A2b adenosine receptor regulating platelet function. J Throm Haemost 2010; 8: 817–827
   PubMed Web of Science ®Google Scholar
• Seamon KB, Daly JW. Activation of adenylate cyclase by the diterpene forskolin does not require the guanine nucleotide regulatory protein. J Biol Chem 1981; 256: 97–99
   Google Scholar
• Iyú D, Jüttner M, Glenn JR, White AE, Johnson AJ, Fox SC, Heptinstall S. PGE1 and PGE2 modify platelet function through different prostanoid receptors. Prostaglandins Other Lipid Mediat 2010; 94: 9–16
   Google Scholar
• Smith JP, Haddad EV, Downey JD, Breyer RM, Boutaud O. PGE2 decreases reactivity of human platelets by activating EP2 and EP4. Thromb Res 2010; 126: 23–29
   Google Scholar
• Iyú D, Glenn JR, White AE, Johnson A, Fox SC, Heptinstall S. The role of prostanoid receptors in mediating the effects of PGE2 on human platelet function. Platelets 2010; 21: 329–342
   PubMed Web of Science ®Google Scholar
• Iyú D, Glenn JR, White AE, Fox SC, van Giezen H, Nylander S, Heptinstall S. Mode of action of P2Y12 antagonists as inhibitors of platelet function. Thromb Haemost 2011; 105: 96–106
   PubMed Web of Science ®Google Scholar
• Iyú D, Glenn JR, White AE, Fox SC, Heptinstall S. Adenosine derived from ADP can contribute to inhibition of platelet aggregation in the presence of a P2Y12 antagonist. Arterioscler Thromb Vasc Biol 2010; 31: 416–422
   Google Scholar
• Fox SC, Behan MWH, Heptinstall S. Inhibition of ADP-induced intracellular Ca2+ responses and platelet aggregation by the P2Y12 receptor antagonists AR-C69931MX and clopidogrel is enhanced by prostaglandin E1. Cell Calcium 2004; 35: 39–46
   PubMed Web of Science ®Google Scholar
• Cattaneo M, Lecchi A. Inhibition of P2Y12 receptor by adenosine diphosphate potentiates the antiplatelet effects of prostacyclin. J Thromb Haemost 2007; 5: 577–582
   PubMed Web of Science ®Google Scholar
• Kuriyama S, Kashiwagi H, Yuhki KI, Kojima F, Yamada T, Fujino T, Hara A, Takayama K, Maruyama T, Yoshida A, et al. Selective activation of the prostaglandin E2 receptor subtype EP2 or EP4 leads to inhibition of platelet aggregation. Thromb Haemost 2010; 104: 796–803
   PubMedGoogle Scholar
• Philipose S, Konya V, Sreckovic I, Marsche G, Lippe IT, Peskar BA, Heinemann A, Schuligoi R. The prostaglandin E2 receptor EP4 is expressed by human platelets and potently inhibits platelet aggregation and thrombus formation. Arterioscler Thromb Vasc Biol 2010; 30: 2416–2423
   PubMedGoogle Scholar
• Klabunde RE. Dipyridamole inhibition of adenosine metabolism in human blood. Eur J Pharmacol 1983; 93: 21–26
   PubMed Web of Science ®Google Scholar
• Dawicki DD, Agarwal KC, Parks RE. Role of adenosine uptake and metabolism by blood cells in the antiplatelet actions of dipyridamole, dilazep and nitrobenzylthioinosine. Biochem Pharmacol 1985; 34: 3965–3972
   Google Scholar
• Gamboa A, Abraham R, Diedrich A, Shibao C, Paranjape SY, Farley G, Biaggioni I. Role of adenosine and nitric oxide on the mechanisms of action of dipyridamole. Stroke 2005; 36: 2170–2175
   Google Scholar
• Chakrabarti S, Freedman JE. Dipyridamole, cerebrovascular disease and the vasculature. Vascular Pharmacol 2008; 48: 143–149
   PubMed Web of Science ®Google Scholar
• Lee K, Kim JY, Yoo BS, Yoon J, Hong MK, Ahn MS, Choe H, Lee SH. Cilostazol augments the inhibition of platelet aggregation in clopidogrel low-responders. J Thromb Haemost 2010; 8: 2578–2579
   Google Scholar
• Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045–1057
   PubMed Web of Science ®Google Scholar
• Nainggolan L, Miller R. 17 December (2010). No US approval for ticagrelor yet; FDA requests further analysys of PLATO. The heart.org. <http://www.theheart.org/article/1164221.do?utm_campaign=newsletter&utm_medium=.email&utm_source=(2010)1217_breakingNews> Accessed (2010) Dec 20.
   Google Scholar
• Gajos G, Rostoff P, Undas A, Piwowarska W. Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol 2010; 55: 1671–1678
   PubMed Web of Science ®Google Scholar